|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
1985-4-15
|
|
pubmed:abstractText |
Twenty-six evaluable patients with advanced epithelial ovarian cancer were treated with mitoxantrone at a dosage of 12 mg/m2 every three weeks. One patient had a partial response; four, stable disease; the remainder progressed. Mitoxantrone used in this dosage and schedule has minimal activity in patients with previously treated epithelial ovarian cancer.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
0277-3732
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
7
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
737-9
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:6528868-Adult,
pubmed-meshheading:6528868-Aged,
pubmed-meshheading:6528868-Anthraquinones,
pubmed-meshheading:6528868-Drug Administration Schedule,
pubmed-meshheading:6528868-Drug Evaluation,
pubmed-meshheading:6528868-Female,
pubmed-meshheading:6528868-Humans,
pubmed-meshheading:6528868-Leukopenia,
pubmed-meshheading:6528868-Middle Aged,
pubmed-meshheading:6528868-Mitoxantrone,
pubmed-meshheading:6528868-Ovarian Neoplasms
|
|
pubmed:year |
1984
|
|
pubmed:articleTitle |
Mitoxantrone (NSC-301739) in patients with advanced ovarian carcinoma. A phase II study of the Gynecologic Oncology Group.
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.
|
